1. Home
  2. FITB vs NTRA Comparison

FITB vs NTRA Comparison

Compare FITB & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FITB

Fifth Third Bancorp

HOLD

Current Price

$54.54

Market Cap

33.2B

Sector

Finance

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$212.34

Market Cap

32.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FITB
NTRA
Founded
1858
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.2B
32.9B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
FITB
NTRA
Price
$54.54
$212.34
Analyst Decision
Buy
Strong Buy
Analyst Count
17
14
Target Price
$53.88
$253.79
AVG Volume (30 Days)
17.3M
1.2M
Earning Date
01-20-2026
02-26-2026
Dividend Yield
2.94%
N/A
EPS Growth
12.42
N/A
EPS
3.53
N/A
Revenue
$8,355,000,000.00
$2,116,676,000.00
Revenue This Year
$55.13
$33.95
Revenue Next Year
$8.83
$16.72
P/E Ratio
$15.39
N/A
Revenue Growth
5.09
38.17
52 Week Low
$32.25
$125.38
52 Week High
$55.36
$256.36

Technical Indicators

Market Signals
Indicator
FITB
NTRA
Relative Strength Index (RSI) 68.05 38.84
Support Level $52.86 $195.46
Resistance Level $55.35 $236.58
Average True Range (ATR) 1.39 8.58
MACD 0.30 -3.40
Stochastic Oscillator 86.39 30.57

Price Performance

Historical Comparison
FITB
NTRA

About FITB Fifth Third Bancorp

Fifth Third Bancorp is a midsize regional bank in the US, with total assets of over $210 billion as of December 2025. The bank is set to close its acquisition of Comercia on Feb. 1, 2026. Headquartered in Cincinnati, Ohio, Fifth Third has a strong presence in the US Midwest and is currently expanding in the US Southeast. The bank provides a diversified set of financial services in retail banking, commercial banking, card and Treasury management, wealth and asset management, and capital markets.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: